CD20, His & Avi, Human
CD20, His & Avi, Human

Immobilized Human CD20 at 1 μg/ml (100 μl/Well), dose response curve for rituximab with the EC50 of 0.8 μg/ml determined by ELISA.

CD20, His & Avi, Human

Immobilized CD20, His & Avi, Human, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 6.97 μg/ml determined by ELISA.

CD20, His & Avi, Human

CD20, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CD20, His & Avi, Human

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117 ) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
Z03630
¥65,290.00

Ask us a question
Product Introduction
Species Human
Protein Construction
CD20 (Ile141-Ser188)
Accession # P11836		 Poly-His Avi
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level ≤ 1 EU/μg of protein by LAL method
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized CD20, His & Avi, Human at 5μg/ml (100μl/well) on the plate can bind Anti-CD20 Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System E. coli
Theoretical Molecular Weight 16.8 kDa
Apparent Molecular Weight 16.8 kDa, on Bis-Tris PAGE
Formulation Supplied as 0.22μm filtered solution in 20mM PB, 10% Glycerol, 0.4M Urea, 1mM GSH, 0.1mM GSSG (pH 7.0).
Concentration Please refer to the COA for the specific lot.
Storage & Stability Valid for 6 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Examples
  • CD20, His & Avi, Human
    • CD20, His & Avi, Human

    Immobilized Human CD20 at 1 μg/ml (100 μl/Well), dose response curve for rituximab with the EC50 of 0.8 μg/ml determined by ELISA.

  • CD20, His & Avi, Human
    • CD20, His & Avi, Human

    Immobilized CD20, His & Avi, Human, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 6.97 μg/ml determined by ELISA.

  • CD20, His & Avi, Human
    • CD20, His & Avi, Human

    CD20, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117 ) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
Synonyms MS4A1; CD20; MS4A-1; B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 11

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.